-
公开(公告)号：US20210317218A1
公开(公告)日：2021-10-14
申请号：US17150789
申请日：2021-01-15
Inventor： Angel LOPEZ , Paul FOSTER
IPC: C07K16/28 , A61K45/06 , A61K31/00 , A61K31/57 , A61K39/395
Abstract: A method of reducing IL-4 and/or IL-13 levels in the lung of a mammal with elevated levels thereof, includes the step of administering to the mammal an effective amount of a βc receptor blocker capable of blocking the binding of all three of IL-3, IL-5 and GM-CSF to the βc common chain to thereby reduce the IL-4 and/or IL-13 levels.
-
2.发明申请公开(公告)号：US20200055943A1
公开(公告)日：2020-02-20
申请号：US16362581
申请日：2019-03-22
Inventor： Angel LOPEZ , Paul FOSTER
IPC: C07K16/28 , A61K39/395 , A61K31/57 , A61K31/00 , A61K45/06
Abstract: A method of reducing IL-4 and/or IL-13 levels in the lung of a mammal with elevated levels thereof, includes the step of administering to the mammal an effective amount of a βc receptor blocker capable of blocking the binding of all three of IL-3, IL-5 and GM-CSF to the βc common chain to thereby reduce the IL-4 and/or IL-13 levels.
-
3.发明公开公开(公告)号：US20240076393A1
公开(公告)日：2024-03-07
申请号：US18449598
申请日：2023-08-14
Inventor： Angel LOPEZ , Paul FOSTER
IPC: C07K16/28 , A61K31/00 , A61K31/57 , A61K39/395 , A61K45/06
CPC classification number: C07K16/2866 , A61K31/00 , A61K31/57 , A61K39/3955 , A61K45/06
Abstract: A method of reducing IL-4 and/or IL-13 levels in the lung of a mammal with elevated levels thereof, includes the step of administering to the mammal an effective amount of a βc receptor blocker capable of blocking the binding of all three of IL-3, IL-5 and GM-CSF to the βc common chain to thereby reduce the IL-4 and/or IL-13 levels.
-
公开(公告)号：US20210228639A1
公开(公告)日：2021-07-29
申请号：US17194855
申请日：2021-03-08
Applicant: Mesoblast, Inc. , Central Adelaide Local Health Network Inc
Inventor： Simon Andrea Koblar , Stan Gronthos , Agnieszka Arthur
IPC: A61K35/28 , C12N5/0775 , A61K9/00 , A61K38/19
Abstract: The present disclosure provides methods of improving cerebral function or preventing loss of cerebral function and/or treating or preventing a movement disorder and/or regenerating cerebral neurons in a subject who has suffered a stroke, the method comprising administering to the subject a population of cells enriched for STRO-1+ cells and/or progeny thereof and/or soluble factors derived therefrom.
-
公开(公告)号：US20200079858A1
公开(公告)日：2020-03-12
申请号：US16493845
申请日：2018-03-14
Applicant: UNIVERSITY OF SOUTH AUSTRALIA , CENTRAL ADELAIDE LOCAL HEALTH NETWORK INC. , SOCIETE DE COMMERCIALISATION DES PRODUITS DE LA RECHERCHE APPLIQUEE SOCPRA SOCPRA SCIENCES SANTE ET
Inventor： Jeffrey Victor LEYTON , Eric MARSAULT , Simon BEAUDOIN , Pierre-Luc BOUDREAULT , Marc-André BONIN , Angel LOPEZ
Abstract: The present description relates to a conjugated anti-interleukin-5 receptor α-subunit (IL-5Rα) compound comprising cholic acid (ChAc) or a variant thereof, the ChAc conjugated to a non-cell penetrating peptide comprising a nuclear localization sequence (NLS) conjugated to an anti-interleukin-5 receptor α-subunit (IL-5Rα) compound and further conjugated to chemotherapeutic agent and/or a radionuclide.
-
Patent Agency Ranking
公开(公告)号：US20190112378A1
公开(公告)日：2019-04-18
申请号：US15753614
申请日：2015-11-26
Inventor： Angel F. LOPEZ , Claudine S. BONDER , Emma THOMPSON
Abstract: A method of treating or preventing breast cancer (eg invasive ductal carcinoma) and/or cancer associated with elevated levels of either one or both of the IL-3 receptor (IL-3R) and interleukin-3 (IL-3) is disclosed which comprises administering to a subject an IL-3 -inhibiting agent such as an agent which inhibits (eg by blocking) IL-3R.
-
公开(公告)号：US20170312249A1
公开(公告)日：2017-11-02
申请号：US15517755
申请日：2015-10-08
Inventor： Joanna Woodcock , Angel Lopez , Stuart Maxwell Pitson , Michael Susithiran Samuel , Carl Coolen
IPC: A61K31/395 , A61K45/06 , A61K31/452 , A61K31/40 , A61K9/06 , A61K47/10 , A61K9/00
Abstract: The present disclosure relates to modulators of 14-3-3 functionality and their use in methods and compositions for preventing and/or treating various diseases, conditions and states, such as cancer and healing of wounds. Certain embodiments of the present disclosure provide a method of preventing and/or treating a disease, condition or state in a subject associated with altered 14-3-3 protein functionality and/or which would benefit from altering 14-3-3 functionality, the method comprising administering to the subject an effective amount of an agent which inhibits dimerization of the 14-3-3 protein, thereby preventing and/or treating the disease, condition or state in the subject.
-
8.发明申请公开(公告)号：US20170173053A1
公开(公告)日：2017-06-22
申请号：US15237548
申请日：2016-08-15
Applicant: CENTRAL ADELAIDE LOCAL HEALTH NETWORK INC.
Inventor： Joanna Woodcock , Stuart Pitson , Angel Lopez
IPC: A61K31/661 , A61K31/133 , C12Q1/48 , A61K31/16 , A61K31/201 , A61K31/132 , A61K31/14
CPC classification number: A61K31/661 , A61K31/132 , A61K31/133 , A61K31/14 , A61K31/16 , A61K31/201 , C12Q1/485 , G01N2500/02 , G01N2500/20
Abstract: The present invention relates to a method of modulating cellular activity. More particularly, the present invention provides a method of modulating apoptosis by modulating protein 14-3-3 phosphorylation and, thereby, its functionality. The present invention still further extends to methods for identifying agents capable of modulating protein 14-3-3 phosphorylation. The method and molecules of the present invention are useful, inter alia, in the treatment and/or prophylaxis of conditions characterised by unwanted cellular activity, such as unwanted cell survival.
-
公开(公告)号：US20140065241A1
公开(公告)日：2014-03-06
申请号：US14019207
申请日：2013-09-05
Applicant: Adelaide Research & Innovation Pty Ltd , ITEK Ventures Pty Ltd , Central Adelaide Local Health Network Inc.
Inventor： Benedetta SALLUSTIO , Robert MILNE , John LICARI , Andrew Alexander SOMOGYI
IPC: A61K31/4458 , A61K31/7004 , G01N33/50 , A61K38/26 , A61K45/06 , A61K38/28 , A61K33/00
CPC classification number: A61K31/4458 , A61K9/2018 , A61K31/7004 , A61K33/00 , A61K38/26 , A61K38/28 , A61K45/06 , G01N33/5008 , G01N2500/00 , G01N2800/32 , A61K2300/00
Abstract: A method for treating or preventing a disease, condition or state in a subject in need thereof by administering to the subject an effective amount of the (−)-enantiomer of perhexyline or a pharmaceutically acceptable salt, prodrug or derivative thereof, substantially free of the (+)-enantiomer, or pharmaceutical composition containing same. The disease, condition or state may be associated with altered tissue energetics, impaired tissue energetics, altered cardiac tissue energetics, impaired cardiac tissue energetics, altered hepatic tissue energetics, impaired hepatic tissue energetics, and diabetes.
Abstract translation: 一种治疗或预防有需要的受试者的疾病，病症或状态的方法，其通过向所述受试者施用有效量的基本上不含所述的（ - ） - 对映异构体的己烯酰基的（ - ） - 对映异构体或其药学上可接受的盐，前药或衍生物 （+） - 对映异构体或含有它们的药物组合物。 疾病，状况或状态可能与改变的组织能量学，受损的组织能量学，改变的心脏组织能量学，受损的心脏组织能量学，改变的肝组织能量学，肝组织能量损伤和糖尿病有关。
-
10.发明授权公开(公告)号：US12139521B2
公开(公告)日：2024-11-12
申请号：US15865806
申请日：2018-01-09
Inventor： Leanne Michelle Dibbens , Ingrid Eileen Scheffer , Samuel Frank Berkovic , John Charles Mulley , Jozef Gecz
IPC: C12Q1/6883 , A61K48/00 , C07K14/705 , C12Q1/6876 , G01N33/566 , A61K38/00
Abstract: Methods and kits for the diagnosis of illnesses related to protocadherin 19 (PCDH19) protein deficiency or altered PCDH19 protein function are provided, as well as methods and kits for the identification of a predisposition to such illnesses and methods of screening subjects to identify carriers of such illnesses and methods and kits for the therapeutic or prophylactic treatment of PCDH19 deficiency or altered PCDH19 protein function. Further, nucleotide and amino acid sequences corresponding to a complete PCDH19 open reading frame (ORF), mutant sequences encoding non-functional PCDH19 mRNA or altered PCDH19 mRNA are described along with transformed cells and non-human transgenic animals comprising wild-type or mutant PCDH19 ORF nucleotide sequences.
-
-
-
-
-
-
-
-
-
Search Results
12
records
(took 0.029 seconds)
